tetano
Editor, Senior Moderator
Vaccine. 2020 Jan 31. pii: S0264-410X(20)30077-3. doi: 10.1016/j.vaccine.2020.01.051. [Epub ahead of print] [h=1]Innate immunemodulator containing adjuvant formulated HA based vaccine protects mice from lethal infection of highly pathogenic avian influenza H5N1 virus.[/h]
Lu Y[SUP]1[/SUP], Landreth S[SUP]2[/SUP], Liu G[SUP]2[/SUP], Brownlie R[SUP]2[/SUP], Gaba A[SUP]2[/SUP], Littel-van den Hurk SVD[SUP]3[/SUP], Gerdts V[SUP]1[/SUP], Zhou Y[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The highly pathogenic avian influenza (HPAI) H5N1 viruses and their spillover into the human population pose substantial economic and public health threats. Although antiviral drugs have some effect in treating influenza infection, vaccination is still the most effective intervention to prevent possible pandemic outbreaks. We have developed a novel H5 influenza vaccine to improve the world's pandemic preparedness. We produced a hemagglutinin (HA) of HPAI H5N1 virus A/Alberta/01/2014 (AB14) using both mammalian (m) and bacterial (b) expression systems. The purified recombinant proteins were formulated with a proprietary adjuvant (TriAdj) and their efficacy as vaccine candidates was evaluated in mice. Intramuscular delivery of two doses of TriAdj formulated mammalian expressed HA (m-HA/TriAdj) was shown to provide full protection against a lethal challenge of AB14 in mice. In contrast, bacterially expressed HA with TriAdj (b-HA/TriAdj), b-HA without adjuvant, and m-HA without adjuvant resulted in no protection in immunized mice. Furthermore, m-HA/TriAdj elicited significantly higher levels of balanced Th1 and Th2 responses and neutralizing antibody titres. All the mice in the m-HA/TriAdj group survived a lethal AB14 H5N1 challenge and showed no signs of disease or infection as demonstrated by no loss of body weight or detectable virus in the lungs. Our results suggest that m-HA formulated with TriAdj has potential to protect against pandemic H5N1 in the event of its cross over to the human host.
Copyright ? 2020 Elsevier Ltd. All rights reserved.
[h=4]KEYWORDS:[/h] Adjuvant; Influenza A virus H5N1; Recombinant HA vaccine
PMID: 32014270 DOI: 10.1016/j.vaccine.2020.01.051
Lu Y[SUP]1[/SUP], Landreth S[SUP]2[/SUP], Liu G[SUP]2[/SUP], Brownlie R[SUP]2[/SUP], Gaba A[SUP]2[/SUP], Littel-van den Hurk SVD[SUP]3[/SUP], Gerdts V[SUP]1[/SUP], Zhou Y[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The highly pathogenic avian influenza (HPAI) H5N1 viruses and their spillover into the human population pose substantial economic and public health threats. Although antiviral drugs have some effect in treating influenza infection, vaccination is still the most effective intervention to prevent possible pandemic outbreaks. We have developed a novel H5 influenza vaccine to improve the world's pandemic preparedness. We produced a hemagglutinin (HA) of HPAI H5N1 virus A/Alberta/01/2014 (AB14) using both mammalian (m) and bacterial (b) expression systems. The purified recombinant proteins were formulated with a proprietary adjuvant (TriAdj) and their efficacy as vaccine candidates was evaluated in mice. Intramuscular delivery of two doses of TriAdj formulated mammalian expressed HA (m-HA/TriAdj) was shown to provide full protection against a lethal challenge of AB14 in mice. In contrast, bacterially expressed HA with TriAdj (b-HA/TriAdj), b-HA without adjuvant, and m-HA without adjuvant resulted in no protection in immunized mice. Furthermore, m-HA/TriAdj elicited significantly higher levels of balanced Th1 and Th2 responses and neutralizing antibody titres. All the mice in the m-HA/TriAdj group survived a lethal AB14 H5N1 challenge and showed no signs of disease or infection as demonstrated by no loss of body weight or detectable virus in the lungs. Our results suggest that m-HA formulated with TriAdj has potential to protect against pandemic H5N1 in the event of its cross over to the human host.
Copyright ? 2020 Elsevier Ltd. All rights reserved.
[h=4]KEYWORDS:[/h] Adjuvant; Influenza A virus H5N1; Recombinant HA vaccine
PMID: 32014270 DOI: 10.1016/j.vaccine.2020.01.051